Immunovent is a brand dedicated to revolutionizing allergy diagnostics. With over $1. 2 billion spent annually on allergy testing, Immunovent aims to address the issue of misdiagnosis, which affects up to 20% of people with allergy symptoms.

Unlike traditional skin-prick and serum diagnostics that focus on distal areas of the body, Immunovent's Local Antibody Mucosal Brush Diagnostic (LAMB-Dx) test examines the local symptomatic regions, providing more accurate results. The LAMB-Dx test uses a proprietary assay to detect antigen-specific IgE from epithelial mucosal cells, allowing for the proper diagnosis of allergies that are not clinically relevant or have inconsistent results from blood or skin testing. This gentle, rapid, and needle-free test is especially ideal for the pediatric population.

The efficacy of the LAMB-Dx test has been demonstrated through four proof-of-concept studies, and Immunovent is currently optimizing protocols for larger-scale clinical trials. With a team composed of experts in biotech and business, Immunovent aims to launch its first allergy diagnostic by 2016. For more information, visit their website's clinical tab